Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdualag
nivolumab and relatlimab-rmbw · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and pediatric patients age 12 or older with melanoma that is unresectable or metastatic.
LAMPGEN ANALYSIS
Why it matters
A fixed-dose combination targets both PD-1 and LAG-3 in advanced melanoma.
What research teams should watch
Review age and weight-specific labeling and align immune toxicity education and follow-up with infusion workflows.
PRIMARY RECORDS